ASCO25: Imunon Reports Positive Phase II Results for Ovarian Cancer Therapy IMNN-001

Imunon shared promising Phase II OVATION 2 trial results for its ovarian cancer therapy, IMNN-001, at ASCO 2025. Involving 112 patients with newly diagnosed advanced epithelial ovarian cancer, the study compared standard neoadjuvant/adjuvant chemotherapy (N/ACT) with and without intraperitoneal IMNN-001. The IMNN-001 group showed a median 13-month increase in overall survival (OS) and a three-month improvement in progression-free survival (PFS), along with a 6.5-month extension in time without progression or death. The therapy was well-tolerated and demonstrated a favorable safety profile. Imunon’s CEO, Stacy Lindborg, credited the consistent results across groups to the company’s proprietary TheraPlas platform. IMNN-001 is designed to enhance treatment efficacy in women with advanced ovarian cancer who need better options. The FDA recently agreed with the design of Imunon’s planned Phase III OVATION 3 trial, marking a step forward in advancing IMNN-001 for broader clinical use.

10-06-2025